Home > Blog > Advancing dose escalation strategies with bayesian modeling

1 min read

Advancing Dose Escalation Strategies with Bayesian Modeling

Oncology

Learn how our biostatistics and strategic consulting teams collaborated with our biotechnology sponsor to advance dose escalation strategies through Bayesian modeling in a Phase 1/2 study for a novel oncology compound. Our efforts led to real-time, data-driven decision making and reduced trial duration while maintaining patient safety.

A biotechnology sponsor developing an oncology therapy engaged us to support the design and execution of a multicenter, open-label Phase 1/2 dose escalation and expansion study. The sponsor aimed to shorten traditional dose escalation timelines without compromising patient safety, moving beyond conventional 3+3 design limitations.

In this case study, learn how Veristat experts were able to work with the sponsor to solve challenges across:

  • Bayesian CRM implementation

  • Real-time decision support

  • Operational complexity management

  • Safety review committee participation

  • Multi-cycle DLT integration

  • Strategic consultative planning

Download our complete case study "Advancing Dose Escalation Strategies with Bayesian Modeling"

DOWNLOAD

 
Contact us today to learn how we can help:
LET'S TALK

2 min read

Operationalizing Adaptive Design for FDA's One-Trial Era

Sep 22, 2026  Veristat Events

Operationalizing Adaptive Design for FDA's One-Trial Era

October 20, 2026 : 11:00 AM ET

On February 18, 2026, the FDA...

2 min read

Meet Veristat at the iC³ Life Science and Healthcare Innovation Summit

Aug 26, 2026  Veristat Events

Where Life Science Innovation Moves Forward

iC³ Life Science and Healthcare Innovation Summit:

September 24-25, 2026 -...